髋关节与膝关节腔内注射曲安奈德对比酮咯酸:一项随机对照试验
110例(52髋、58膝)中重度影像学原发性骨关节炎患者双盲随机接受超声引导下关节腔内注射酮咯酸或曲安奈德,两组患者报告结局均有统计学显著改善,1周时效应量最大并随时间下降,方差分析显示两组间无显著差异;膝关节注射事后分析提示曲安奈德组疗效稍持久,两组不良事件均较少。
要点
- 髋、膝关节腔内注射酮咯酸或曲安奈德均较注射前有统计学显著改善,1周效应量最大。
- 主要方差分析比较显示酮咯酸与曲安奈德之间无显著差异。
- 膝关节注射事后二次分析提示曲安奈德组疗效稍持久,两组不良事件均较少。
核心结论
- 关节腔内酮咯酸注射对原发性髋、膝骨关节炎的改善与曲安奈德相当。
- 酮咯酸是原发性骨关节炎保守治疗的一种低成本选择,且因其作用机制不同,可能不会加重软骨损伤,若治疗失败也不妨碍早期手术干预。
研究设计与样本
- 非劣效性双盲随机对照试验,共纳入110例(52髋、58膝)影像学中重度原发性髋或膝关节骨关节炎患者。
- 患者随机接受超声引导下关节腔内注射酮咯酸或曲安奈德,在注射前及注射后1周、1个月、3个月收集患者报告结局指标。
- 试验注册号NCT04441112。
主要发现
- 髋、膝关节腔内注射酮咯酸或曲安奈德均使患者报告结局指标出现统计学显著改善。
- 治疗效应量在1周时最大,并随时间下降。
- 主要方差分析比较显示酮咯酸与曲安奈德之间无显著差异。
- 膝关节注射事后二次分析提示曲安奈德组疗效稍持久。
- 两种干预的不良事件均较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinicians commonly utilize intra-articular injections to treat symptomatic primary arthritis. Steroid injections are common yet have immune-modulating effects and can alter gene expression which may delay definitive arthroplasty and further damage cartilage. Nonsteroidal anti-inflammatory injections may offer a safer profile due to their differing mechanism of action; however, there is a relative dearth of information regarding their efficacy. This noninferiority study compares the effectiveness of triamcinolone vs ketorolac in treating symptoms of moderate to advanced primary osteoarthritis of the hip and knee. METHODS: In total, 110 patients (52 hips and 58 knees) with moderate to severe radiographic primary osteoarthritis of the hip or knee were randomized in a double-blinded study to receive an ultrasound-guided intra-articular injection of ketorolac or triamcinolone. Patient-reported outcome measures were collected pre-injection and at 1 week, 1 month, and 3 months. RESULTS: For hips and knees, intra-articular injections with either ketorolac or triamcinolone led to statistically significant improvements in patient-reported outcome measures. The treatment effect size was largest at 1 week and decreased over time. Primary analysis of variance comparisons revealed no significant differences between ketorolac and triamcinolone. For knee injections, post hoc secondary analysis suggests slight added durability in the triamcinolone group. Adverse effects were minimal with both interventions. CONCLUSION: Intra-articular ketorolac injections provide comparable improvement to triamcinolone for primary hip and knee osteoarthritis. Ketorolac is an additional low-cost option for conservative management of primary osteoarthritis, and due to its differing mechanism of action, it may not propagate additional cartilage damage or preclude from early surgical intervention if unsuccessful. TRIAL REGISTRATION NUMBER: NCT04441112.
引用
- Jurgensmeier K, Jurgensmeier D, Kunz DE, et al. Intra-articular Injections of the Hip and Knee With Triamcinolone vs Ketorolac: A Randomized Controlled Trial. J Arthroplasty. 2020. PMID: 32950343. doi:10.1016/j.arth.2020.08.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。